- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Investigating Breast Cancer, the official podcast of the Breast Cancer Research Foundation, examines the latest in breast cancer news with the most respected minds in science.
The series contains insightful conversations with BCRF's scientific leadership and features experts that are taking part in groundbreaking science every day. As the only organization dedicated exclusively to breast cancer research, BCRF’s podcast reflects a multitude of hot topics, examining the promise of scientific discovery. Simply search for Investigating Breast Cancer and subscribe to the channel in your Podcast app, available through any of the players below:
FIND CONVERSATIONS WITH:
- Dr. Larry Norton
- Dr. Marc Hurlbert
- Dr. Judy Garber
- Dr. Charles Perou
- Dr. Mina Bissell
- Dr. Arti Hurria
- Dr. Michael Clarke
- Dr. Debra Barton
- Dr. Anna Maria Storniolo
- Drs. Daniele Gilkes and Paul Macklin
- Dr. Peter Kuhn
- Dr. Jedd Wolchok
- Dr. Jack Cuzick
- Dr. Robert Schneider
- Dr. Alan Ashworth
- Dr. Annette Stanton
- Dr. Michael Wigler
- Dr. Hedvig Hricak
- Dr. Ben Park
- Dr. Joseph Sparano
- Dr. Sofia Merajver
Dr. Larry Norton (click through for full transcript)
Few have a more significant history or deeper relationship with breast cancer research and researchers than Dr. Larry Norton. Dr. Norton is Scientific Director of the Breast Cancer Research Foundation. He is also one of the organization’s founders. Dr. Norton serves as Medical Director of the Evelyn H. Lauder Breast Center at the Memorial Sloan Kettering Cancer Center, and among many other honors and appointments, he was a U.S. Presidential appointee to the National Cancer Advisory Board – the board of directors of the National Cancer Institute.
Dr. Marc Hurlbert (click through for full transcript)
Once you get beyond pink, what is the best path to help put an end to breast cancer – the most common cancer in women worldwide and second leading cause of cancer death in American women, exceeded only by lung cancer? Talk to many people who dedicate their lives to finding a cure, and the answer you’ll hear most often: Research. So where are we with global scientific research into breast cancer – its causes and cures? Which latest findings offer the best hopes, biggest surprises, most frustrating obstacles? How can the research go faster – find hidden clues more quickly? If science is the key to a cure, what steps can we all take to help researchers open the lock? Dr. Marc Hurlbert was formerly Chief Mission Officer of the Breast Cancer Research Foundation
Dr. Judy Garber (click through for full transcript)
Hereditary predisposition to breast cancer – a person’s own genes, passed down from parent to child – remains one of the biggest challenges – and opportunities – in the drive to prevent the disease. Of course, women with mutations in the hereditary breast cancer genes, BRCA1 and BRCA2, have much higher risks of breast and ovarian cancers that often develop early in life. That’s why fully understanding the process that a normal cell must take to transform into a tumor cell in BRCA mutation carriers is – among the wide range of important and potentially life saving scientific research – central not only to new insights and approaches to cancer prevention but also, quite simply, how many families may think about their futures. One of the leaders of that research: Dr. Judy Garber.
Dr. Charles Perou (click through for full transcript)
When many of us hear the word technology or consider the life changing power of new technologies, we think about companies like Google or Apple or Amazon or Tesla. We think about products like internet search or I phones or drone deliveries or even self-driving cars.
Dr. Charles Perou thinks about breast cancer. You might say he sits at the intersection of technology and tumors.
Dr. Mina Bissell (click through for full transcript)
You know the expression, it's what's on the inside that matters. It turns out for that cells including cancer cells, including cancer cells, the outside matters a whole lot too.
Specifically, the interactions between the extracellular matrix in the micro environment, the connections between the outside of the cell and the inside is central to how that cell behaves and for cancer cells, how they might grow, spread or most importantly be stopped.
It's hard to overestimate the magnitude of this breakthrough for biology, cancer research and importantly breast cancer research. This singular discovery rewrote decades of scientific understanding and redirected vast amounts of future research and success. It occurred because of what's been called the controversial insistence of Dr. Mina Bissell.
Dr. Arti Hurria (click through for full transcript)
Among the many important research areas of breast cancer and frankly all cancers is what's called survivorship; quality of life and the ability to live independently. Among older survivors, one area of concern: cognitive decline or memory loss. This is one of the areas that Dr. Arti Hurria studies. Dr. Hurria and her team focus on older, long-term breast cancer survivors looking at memory difference between those who received chemotherapy versus those who did not compared to healthy women of the same age who never had cancer. What might their discoveries offer in terms of predicting potential memory issues among survivors and, importantly, creating interventions to preserve capabilities and the highest possible quality of life?
Dr. Michael Clarke (click through for full transcript)
In 2003, Clarke's lab was the first to identify breast cancer stem cells. Since then, among other findings, Clarke's team has identified two genes critical for stem cell functions including a gene that regulates normal stem cell dormancy which can drive the unpredictable length of time when tumor cells exist quietly without clinical manifestation. It's one of the most pressing problems in breast cancer responsible for late relapses. What's next from Dr. Clarke and his lab? What ideas is he exploring that might help prevent relapse?
Dr. Debra Barton (click through for full transcript)
Dr. Debra Barton is the Mary Lou Willard French professor of nursing at the University of Michigan School of Nursing. She has spent her career looking at symptom management from multiple perspectives and finding ways to use more than one intervention to reduce symptoms with minimal to no side-effects. She's also been a BCRF grantee since 2008.
Dr. Anna Maria Storniolo (click through for full transcript)
What does the beginning of breast cancer look like? What happens at the very start that turns normal breast tissue into the first stages of cancer, and by recognizing these early molecular changes and pathway alternations, could we not only improve our understanding of the evolution of breast cancer, but also one might hope find a way to stop it before it even begins in this conversation with Dr. Storniolo.
Drs. Daniele Gilkes and Paul Macklin (click through for full transcript)
Today's conversation with Dr. Gilkes and Dr. Macklin proves a simple math problem: two is better than one. Actually today's conversation also tackles some really complicated math and science. Specifically, how applied mathematics and tumor biology are coming together to drive important new research in breast cancer and metastasis.
Dr. Peter Kuhn (click through for full transcript)
What if we could track where the cancer is moving through the body, not by evasive biopsies, but rather through a common procedure we go through nearly anytime we visit a doctor. A simple blood draw. That's just one of the innovations discussed with Dr. Peter Kuhn.
Dr. Jedd Wolchok (click through for full transcript)
Immunotherapy – treating a disease by inducing, enhancing, or suppressing an immune response – remains one of the biggest hopes in terms of potentially finding a breast cancer cure. And yet, it also remains an incredibly challenging discipline. What works for one type of cancer may not for another.
Dr. Jack Cuzick (click through for full transcript)
Well-designed randomized clinical trails may provide information about prevention strategies and effective treatments for women at risk of or diagnosed with breast cancer. A major limitation of clinical trials, however, is that results apply to the trial group as a whole, but not necessarily to each individual woman. That's because individual responses are influenced by the patient's and the tumor's unique DNA or genetic profile.
Dr. Robert Schneider (click through for full transcript)
Most women who die of breast cancer die from metastatic disease, the spread of tumor cells to different parts of the body. Metastasis often results following treatment failure, but it also can occur decades after what was thought to be successful treatment. Currently, no curative therapies exist for metastatic breast cancer. But today, the race to develop effective treatments for this disease is a key focus of some extraordinary research, much of it centering on cancer cells’ protein synthesis machinery and a protein called mTOR. What’s the status of this research – and what might some practical outcomes look like?
Dr. Alan Ashworth (click through for full transcript)
It sounds like something out of Game of Thrones: Attack the weakness. Today, we apply the phrase to a more important and real battle – the one against breast cancer.
As you’ll hear, Dr. Alan Ashworth is part of a team that developed something called PARP Inhibitors and, quite creatively, identified ways to use them to attack the weaknesses of various cancers, including breast cancer. How do PARP Inhibitors work and what might they mean for attacking cancers’ weaknesses?
Dr. Annette Stanton (click through for full transcript)
This is an outstanding and thoughtful conversation on stress, breast cancer, and the science of survivorship. We all, of course, experience stress, work, family, money, but what about health, in particular, cancers like breast cancer? Obviously dealing with illness, indeed dealing with ongoing treatments and procedures brings stress to a whole new level. How can women undergoing breast cancer treatments manage that stress? Perhaps more significantly, are there scientifically researched and proven approaches that not only help increase their health and wellbeing, but even improve the recovery process and results? This is the important work that Dr. Annette Stanton does.
Dr. Michael Wigler (click through for full transcript)
Breast cancer and technology. At first glance, they seem like totally separate topics. After this conversation, you’ll not only better understand the connection, but you’ll be waiting to learn what comes next. As you’ll hear, thanks to technology developed by our guest Dr. Michael Wigler – in collaboration with BCRF colleague James Hicks – researchers can now study breast cancer at the single-cell level, setting the stage for the development of new diagnostic tools that will aid in therapeutic management of the disease. Since then, Dr. Wigler has continued to go small – focusing on the interactions between cancer cells and the host microenvironment. It’s a fascinating approach.
Dr. Hedvig Hricak (click through for full transcript)
Dr. Hedvig Hricak: is, among many other roles, Chairman, Department of Radiology at Memorial Sloan Kettering Cancer Center. She was honored by BCRF with the 2018 Jill Rose Award for outstanding research excellence. As you will hear, Dr. Hricak is extraordinary – not just in her work helping merge imaging technology with molecular medicine, but also in her teaching across borders.
Dr. Ben Park (click through for full transcript)
How does cancer grow? Why do some cancers react positively to treatment while others seem to resist? Understanding these relationships, the genetic events and cell-to-cell interactions that lead to cancer, not only can provide better understanding of how cancer develops, but also drive potential new targets for drug development. Understanding these relationships also essential to the incredible work being done by Dr. Ben Ho Park.
Dr. Joseph Sparano (click through for full transcript)
It was among the biggest cancer news stories of the year: A new study – the largest breast cancer treatment trial ever conducted – showed no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. As the Washington Post described, that means: “most patients who have an intermediate risk of a cancer recurrence — a group that numbers 65,000 women a year in the United States — can avoid chemotherapy and its often debilitating side effects.” The TAILORx trial, as it is known, is helping change everyday procedures in the everyday lives of patients around the world.
Dr. Sofia Merajver (click through for full transcript)
As you’ll hear, Dr. Merajver – who has been a BCRF Investigator since 2004 – discusses her unique, collaborative and extraordinarily human approach to one of the most significant science questions of our time: How to find new strategies for the prevention and treatment of metastatic breast cancer.